Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
To assess, under daily practice conditions, the safety profile and the efficacy of a new
formulation of alfuzosin administered once daily (Xatral XL) in patients with lower urinary
tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).